
- /
- Supported exchanges
- / US
- / SPRB.PINK
Spruce Biosciences Inc (SPRB PINK) stock market data APIs
Spruce Biosciences Inc Financial Data Overview
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Spruce Biosciences Inc data using free add-ons & libraries
Get Spruce Biosciences Inc Fundamental Data
Spruce Biosciences Inc Fundamental data includes:
- Net Revenue: 2 909 K
- EBITDA: -57 973 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Spruce Biosciences Inc News

Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences, Inc. (SPRB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -...


Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
SOUTH SAN FRANCISCO, Calif., June 12, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies f...

Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board SOUTH SAN FRANCISCO, Calif., May 25, 2023--(BUSINESS WIRE)--Spruc...

Spruce Biosciences to Participate in the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 24, 2023--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies fo...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.